EFTA02656034.pdf

From: jeffrey E. <[email protected]> Sent: Friday, March 24, 2017 11:25 AM To: rshimonymd thanks for the article on evolcumab, it =s clear that it reduces the Id' MARKER. much less clear =n its role in reduction of incidents? you were a mensch =ith terje =AO please note The information contained in this=communication is confidential, may be attorney-client privileged, mayconstitute inside information, and is intended only for the use of the=addressee. It is the property of JEE Unauthorized use, disclosure or=copying of this communication or any part thereof is strictly prohibite= and may be unlawful. If you have received this communication in err=r, please notify us immediately by return e-mail or by e-mail to [email protected]<=a>, and destroy this communication and all copies thereof, including=all attachments. copyright -all rights reserved --001a11c14dfab8124a054b783edl-- conversation-id 49643 date-last-viewed 0 date-received 1490354703 flags 8590195713 gmail-label-ids 7 6 remote-id 698794 1 EFTA_R1_01901473 EFTA02656034